Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9018395
APP PUB NO 20140057894A1
SERIAL NO

13981834

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Disclosed herein is a compound of Formula I: wherein X, R1, R2, and R3 are as defend herein, or a pharmaceutically acceptable salt thereof to allow the drug to penetrate the cell membrane; or a prodrug, or the compound is labeled with a detectable label or an affinity tag thereof. Also disclosed is a pharmaceutical composition, a method of treating a disorder mediated by melanocortin-4 receptors, and a method of treating obesity using the compounds described.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
UNIVERSITE DE MONTREALQUEBEC CAN QUEBEC

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bouvier, Michel Montreal, CA 21 88
Chantigny, Yves Pincourt, US 8 8
Dagneau, Philippe St-Laurent, US 3 0
Gingras, Stéphane Montreal, CA 7 19
Marinier, Anne Kirkland, US 26 211
René, Patricia Montreal, CA 4 1
Ruel, Réjean Saint-Lambert, US 6 33

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 28, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00